Regulation & Compliance

An AI procurement firm has joined the council that sets government purchasing standards. Can it solve bureaucracy or will it create new digital gatekeepers?

As FDA rules on peptides shift, a new AI platform aims to give doctors clarity, separating solid science from speculation in the booming longevity market.

Simplify launches two tax-aware funds, LQ and DINE, using a unique swap-based design to help investors keep more of what they earn.

The world's leading expert network, GLG, launches an AI-powered platform, aiming to merge machine speed with human insight for a new era of research.

The largest-ever study on school phone bans confirms huge drops in phone use and improved student well-being, but the impact on test scores is more complex.

A new partnership aims to solve banking woes for the multi-billion-dollar peptide and IV therapy industries, long deemed 'too risky' by traditional finance.

Tunnell Consulting's perfect CMMC score reveals a cost-effective enclave strategy, challenging the belief that compliance must be an expensive overhaul.

As AI-generated content floods the internet, PeakMetrics launches advanced tools to help organizations distinguish real narratives from manipulated ones.

As acquisition costs soar, Fast Simon hires a partnership director to arm agencies with AI tools, turning on-site traffic into much-needed revenue.

Recognized on the CB Insights AI 100 list, Rhino Federated Computing pioneers a new era of secure, decentralized AI for highly regulated industries.

With 21% of voice actors reporting job losses to AI, a national association is taking its fight to D.C. to demand policy action and protect human creativity.

Forrester's new report highlights Airia as enterprises grapple with governing the new wave of autonomous, agentic AI systems that defy old rules.

With compliance costs soaring, Spring Labs' $5M funding round will scale its AI agents to automate the execution of regulatory tasks for financial firms.

A new national agreement brings QuVa Pharma's AI-powered drug diversion software to thousands of hospitals, promising a high-tech solution to a hidden crisis.

With veteran Jason Montrie at the helm, Alerion Advisors aims to build an integrated platform to solve health plans' biggest operational headaches.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

A new FDA-cleared system offers hope against postpartum hemorrhage, the leading cause of maternal death, earning its maker a prestigious Edison Award.

Zywave's Spring 2026 release promises to slash administrative work with new AI agents, but can its execution live up to the ambitious vision for growth?

A new partnership aims to replace perception with performance data, allowing crypto projects to vet liquidity partners with unprecedented clarity.

As federal funding for psychedelic therapy surges, practitioners warn that a critical lack of patient preparation and integration support could undermine healing.